Certified Pediatric Hematology Oncology Nurse (CPHON) 2025 – 400 Free Practice Questions to Pass the Exam

Acute Chest Syndrome (ACS) is a serious complication often seen in patients with sickle cell disease, characterized by pulmonary infiltrates and respiratory distress. The management of ACS typically involves supportive care that addresses the underlying causes and associated symptoms.

The use of immunosuppressive therapy is not standard in the treatment of Acute Chest Syndrome. This therapy, which is primarily aimed at suppressing the immune response, would be counterproductive in this context since ACS is often triggered by infection, vaso-occlusive episodes, or pulmonary events related to sickle cell disease. Instead, the focus is on improving oxygenation, managing pain, and addressing any infections with antibiotics to prevent further complications.

Antibiotics play a key role in treating potential infections that can contribute to or exacerbate ACS. Additionally, pain management is essential for comfort and to reduce stress on the respiratory system. Increased oxygenation is also critical to ensure adequate oxygen delivery to tissues and to alleviate hypoxemia, which is a common issue in ACS.

Therefore, the correct choice represents an approach that is not indicated for the management of Acute Chest Syndrome, making it distinctly different from the other treatment modalities commonly employed in its care.